Beam Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017
Revenue	377.71	60.92	51.84	0.02	0.02	0	0
Revenue Growth (YoY)	520.01%	17.51%	215916.67%	33.33%	-	-	-
Gross Profit	377.71	60.92	51.84	0.02	0.02	0	0
Selling, General & Admin	116.81	87.81	57.22	29.61	20.55	11.87	2.02
Research & Development	437.38	311.59	387.09	103.18	54.62	33.87	5.86
Operating Expenses	554.19	399.4	444.31	132.78	75.17	45.74	7.88
Operating Income	-176.49	-338.48	-392.47	-132.76	-75.15	-45.74	-7.88
Other Expense / Income	-45.32	-52.8	-21.83	61.83	3.17	69.52	0.12
Pretax Income	-131.16	-285.68	-370.64	-194.59	-78.33	-115.26	-8
Income Tax	1.37	3.41	0	0	0	0	0
Net Income	-132.53	-289.09	-370.64	-194.59	-78.33	-115.26	-8
Preferred Dividends	0	0	0	1.28	12.71	2.07	1.69
Net Income Common	-132.53	-289.09	-370.64	-195.87	-91.04	-117.33	-9.69
Shares Outstanding (Basic)	77	70	64	47	6	3	0
Shares Outstanding (Diluted)	77	70	64	47	6	3	0
Shares Change	10.19%	9.01%	37.43%	621.24%	123.90%	1019.44%	-
EPS (Basic)	-1.72	-4.13	-5.77	-4.19	-14.05	-40.54	-37.47
EPS (Diluted)	-1.72	-4.13	-5.77	-4.19	-14.05	-40.54	-37.47
Free Cash Flow	-182.93	-26.42	-113.08	-112.1	-84.52	-33.42	-3.05
Free Cash Flow Per Share	-2.37	-0.38	-1.76	-2.40	-13.04	-11.55	-11.81
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	-	-
Operating Margin	-46.73%	-555.61%	-757.01%	-553166.67%	-417522.22%	-	-
Profit Margin	-35.09%	-474.54%	-714.91%	-816120.83%	-505777.78%	-	-
Free Cash Flow Margin	-48.43%	-43.37%	-218.11%	-467075.00%	-469561.11%	-	-
EBITDA	-111.15	-271.53	-363.19	-189.86	-74.82	-114.61	-7.99
EBITDA Margin	-29.43%	-445.72%	-700.54%	-791070.83%	-415683.33%	-	-
Depreciation & Amortization	20.01	14.15	7.45	4.74	3.5	0.65	0.01
EBIT	-131.16	-285.68	-370.64	-194.59	-78.33	-115.26	-8
EBIT Margin	-34.73%	-468.94%	-714.91%	-810800.00%	-435144.44%	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).